Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…Continue
Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments
Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by researchers from the Fred Hutchinson Cancer Research Center found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic…Continue
Added by Peter Hofland, PhD on February 4, 2013 at 10:00pm — No Comments
A large study reports that a new real-time performance tracking system, which monitors adherence to five National Quality Forum endorsed quality care metrics for breast and colon cancer, significantly improved quality standard adherence rates over a four-year period in a group of 64 cancer centers participating in the Rapid Quality Reporting System or RQRS “beta test.” Use of the system also reduced reported…Continue
Added by Peter Hofland, PhD on November 27, 2012 at 6:30pm — No Comments
New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012).
Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, commented Fausto Roila, M.D. from Medical Oncology Department, Terni,…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 9:30pm — No Comments
The results of a new phase III head-to-head study comparing crizotinib, a targeted therapy, with standard chemotherapy show that crizotinib is more effective than standard chemotherapy for patients with advanced, ALK-positive lung cancer. The results were prensented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012).…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 6:00am — No Comments
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…Continue
Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
The Death of his first wife makes improving the Quality of Life (QoL) for patients with a brain tumor very personal for Mike Robbins, associate director of the Thomas K. Hearn Jr. Brain Tumor Research Center at Wake Forest Baptist Medical Center. Robbins knows all too well that the likely outcome when patients are diagnosed with brain tumors that are "high grade" may not always be positive.
Added by Peter Hofland, PhD on June 26, 2012 at 11:00am — No Comments
Results from the phase III CLEOPATRA study showed that women with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of pertuzumab (Perjeta™, Genentech/Roche), trastuzumab (Herceptin®, Genentech/Roche) and docetaxel chemotherapy, compared to trastuzumab and docetaxel chemotherapy alone. in the Phase III . These data will be submitted for presentation at an upcoming medical meeting.…
Added by Peter Hofland, PhD on June 21, 2012 at 5:30pm — No Comments
The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL. offered a wealth of new scientific and clinical data. It is expected that this year's event will have a significant impact on the patients treatment plans.
After reviewing this years meeting, a new type of targeted therapy was of particular interest to reviewer Daphna Halpern, Director of Oncology at…
Added by Peter Hofland, PhD on June 14, 2012 at 6:00am — No Comments
Late breaking data from a Phase III study presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) shows that the oral investigational drug trametinib (GlaxoSmithKline) delayed tumor growth and extended survival for patients with advanced melanoma who have BRAF mutations, compared with standard chemotherapy. This is the first Phase III trial…Continue
Added by Peter Hofland, PhD on June 5, 2012 at 3:30pm — No Comments
Results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102) conducted on a previously reported Phase II study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with the trial drug in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression. Full results of the…Continue
Added by Peter Hofland, PhD on May 16, 2012 at 3:30pm — No Comments
A large, retrospective study published in the Journal of Clinical Oncology, a tri-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), shows that children of childhood cancer survivors who received prior treatment involving radiation to testes or ovaries and/or chemotherapy with alkylating agents do not have an increased risk for birth…Continue
Added by Peter Hofland, PhD on December 12, 2011 at 6:00pm — No Comments
Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) presented at the 53rd Annual Meeting American Society of Hematology being held December 10 to 13, 2011 in San Diego, CA, shows durable complete remissions and treatment…Continue
Added by Peter Hofland, PhD on December 12, 2011 at 4:30pm — No Comments
New research presented at the 53rd Annual Meeting of the American Society of Hematology being held in San Diengo, CA, December 10 - 13, concludes that patients with limited-stage Hodgkin lymphoma treated with a standard chemotherapy regimen have better overall survival rates compared with those receiving a radiation-based treatment.
Patients with limited-stage Hodgkin lymphoma (HL) are often treated with…
Added by Peter Hofland, PhD on December 11, 2011 at 9:30am — No Comments
The U.S. Food and Drug Administration today approved cetuximab Erbitux (Bristol-Myers Squibb)for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.
Combined with chemotherapy, cetuximab extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Cetuximab already is FDA-approved for certain types of colon…
Added by Peter Hofland, PhD on November 7, 2011 at 11:30am — No Comments
The U.S. Food and Drug Administration (FDA) today authorized Circadian Technologies Ltd. to initiate clinical trials with its investigational new drug VGX-100. The first Phase I trials will study VGX-100 in patients with a variety of late stage cancers.
VGX-100 is a fully human antibody that acts against the human VEGF-C protein. Treatment for…
Added by Peter Hofland, PhD on October 31, 2011 at 7:00am — No Comments
Challenging a half-century-old theory about why chemotherapy agents target cancer, scientists at Dana-Farber Cancer Institute have devised a test that can predict how effective the drugs will be by determining whether a patient’s tumor cells are already “primed” for death.
In a study published online by the journal Science on October 27, 2011…
Added by Peter Hofland, PhD on October 27, 2011 at 5:00pm — No Comments
Patients with a high degree of African ancestry had a greater incidence of high-risk neuroblastoma and poorer outcomes, according to preliminary results presented at the Fourth AACR Conference on The Science of Cancer Health Disparities, held in Washington DC, September 18-21, 2011.
“There are common genetic variants that are associated with the development of high-risk neuroblastoma and a poor outcome,” said Navin R. Pinto, M.D., instructor of pediatrics…
Added by Peter Hofland, PhD on September 19, 2011 at 11:00am — No Comments
Added by Peter Hofland, PhD on July 19, 2011 at 4:30pm — No Comments
Added by Peter Hofland, PhD on July 18, 2011 at 11:30am — No Comments